Boehringer Ingelheim received good news from the FDA today when its anticlotting drug, Pradaxa was approved to prevent strokes and irregular heartbeat. Thus BI beats its competitors to market with a drug to serve the $12 B anticlotting market.
Warfarin has been the standard in this segment for a very long time, but Norman Stockbridge, director of FDA's cardiovascular and renal products, notes that Pradaxa did better in clinical trials. Pradaxa could be a $4 B per year drug - a megablockbuster - and by reaching market first has a leg up on Bayer/J&J's rivaroxaban, BMS/Pfizer's pixaban and Merck/Portola's betrixaban. See Fierce Biotech.
First to market = CASH and share.
Posted by Bruce Lehr October 20th 2010.
Comments